The University of Oxford-led RECOVERY trial has been testing a range of potential treatments for patients admitted to hospital for COVID-19 since March 2020. The benefit of baricitinib was consistent regardless of which other COVID-19 treatments the patients were also receiving, including corticosteroids, tocilizumab, or remdesivir. Patients receiving baricitinib were also more likely to be discharged alive within 28 days (80% vs. 78%, age-adjusted rate ratio 1.10, 95% CI 1.04-1.15; p<0.001). But I saw it as my duty to take part in the RECOVERY trial, because I knew that no matter what happened to me, I was doing something positive to help others. ‘This is promising news from the government-funded RECOVERY trial and shows, once again, how the UK is leading the world in identifying life-saving treatments for NHS patients.
